JPRN-UMIN000001570已完成2 期
A phase II study of the Cladribine and Rituximab combination therapy for relapsed and refractory indolent B-cell Non-Hodgkin's Lymphoma. - A phase II study of Cladribine and Rituximab therapy for relapsed indolent B-cell Non-Hodgkin's Lymphoma.
refractory lymphoma treatment study group0 个研究点目标入组 45 人开始时间: 2008年12月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.previous exposures of cladribine, fludarabine, or pentostatin. 2.treatment histories of more than one allogenic stem cell transplantasion or more than 2 times of autologous stem cell transplantation. 3.transformed case at registration. 4.past history of glaucoma. 5.presence of active infection. 6.HBs Ag posivtive, HCV Ab positive, HIV Ab positive. 7.presence of lymphoma cells more than 5000/mm3 in periperal blood. 8.past history of severe drug allergy. 9.presence of other active malignancy. 10.diabetis melitus recieving insulin therapy. 11.severe mental disorder. 12.autoimmune hemolytic anemia. 13.severe bleeding tendency. 14.recieving CSF or blood transfusion within 2 weeks of registration. 15.presence of central nervous involvement (clinical or pathological). 16.pregnant or feeding female. 17.recieving unapproved anti cancer agents within 3 months of registration. 18.judged for inappropriate by other reasons.
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study Comparing Rituximab and Cladribine for Relapsing Multiple SclerosisEUCTR2019-001505-24-NODepartment of Neurology, Division of Clinical Neuroscience, Oslo University Hospital264
已完成
2 期
A Phase II Study of Ibrutinib, Rituximab and mini-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy in very elderly patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)ACTRN12615000551594Australasian Leukaemia and Lymphoma Group80
进行中（未招募）
不适用
Dose-finding study of the substance clofarabine in combination with fixed doses of cytarabine and idarubicine as therapy for patients with acute myeloid leukemia and high risk for treatment failure (CIARA)Patients with acute myeloid leukemia (AML) and high risk for induction failureMedDRA version: 17.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2010-021719-18-DEHannover Medical School
终止
2 期
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative DisorderPost-transplant Lymphoproliferative DisorderNCT04337827Deepa Jagadeesh6
进行中（未招募）
不适用
Clinical Trial with Cladribine (2-CDA) and Pegylated Interpheron Alfa-2a in patients with advanced systemic mastocytosis carrying D816V KIT mutation (or different mutations involving exon 17 of KIT).EUCTR2012-000797-35-ESHospital Virgen de la Salud, Toledo (Spain).